Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBiagetti Biagetti, Betina
dc.contributor.authorSimó Canonge, Rafael
dc.date.accessioned2022-06-14T07:33:46Z
dc.date.available2022-06-14T07:33:46Z
dc.date.issued2021-01-02
dc.identifier.citationBiagetti B, Simó R. GH/IGF-1 Abnormalities and Muscle Impairment: From Basic Research to Clinical Practice. Int J Mol Sci. 2021 Jan 2;22(1):415.
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/11351/7677
dc.descriptionAcromegaly; Growth hormone; Myopathy
dc.description.abstractThe impairment of skeletal muscle function is one of the most debilitating least understood co-morbidity that accompanies acromegaly (ACRO). Despite being one of the major determinants of these patients’ poor quality of life, there is limited evidence related to the underlying mechanisms and treatment options. Although growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels are associated, albeit not indisputable, with the presence and severity of ACRO myopathies the precise effects attributed to increased GH or IGF-1 levels are still unclear. Yet, cell lines and animal models can help us bridge these gaps. This review aims to describe the evidence regarding the role of GH and IGF-1 in muscle anabolism, from the basic to the clinical setting with special emphasis on ACRO. We also pinpoint future perspectives and research lines that should be considered for improving our knowledge in the field.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesInternational Journal of Molecular Sciences;22(1)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMúsculs - Malalties
dc.subjectSomatotropina
dc.subject.meshMuscular Diseases
dc.subject.mesh/metabolism
dc.subject.meshInsulin-Like Growth Factor I
dc.subject.mesh/deficiency
dc.titleGH/IGF-1 Abnormalities and Muscle Impairment: From Basic Research to Clinical Practice
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/ijms22010415
dc.subject.decsenfermedades musculares
dc.subject.decs/metabolismo
dc.subject.decsfactor I de crecimiento insulinoide
dc.subject.decs/deficiencia
dc.relation.publishversionhttps://doi.org/10.3390/ijms22010415
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliationUnitat de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERDEM (ISCIII), Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid33401779
dc.identifier.wos000606291500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record